Chronic Pain Clinical Trial
Official title:
Spanish Language Adaptation of One MORE for Chronic Pain in Latinos
This study will be a single-site, two-arm randomized controlled trial conducted among Spanish-speaking chronic pain patients. Chronic pain patients will be randomized by a computer-generated randomization schedule with simple random allocation (1:1) to either One MORE or a wait-list control condition (WLC). One MORE will be delivered individually either in-person or via a HIPAA compliant virtual meeting platform.
Status | Recruiting |
Enrollment | 34 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Spanish-speaking - Age 18+ - Diagnosed with a chronic pain condition - Average pain in the previous week > or = 3 - Willingness to participate in study interventions and assessments. Exclusion Criteria: - Non Spanish-speaking - Score of 10 or greater ('high risk') on the suicidality subsection of the MINI - Psychotic episode within the last 12 months as deemed by the corresponding subsection of the MINI - Presence of clinically unstable illness judged to interfere with treatment or study procedures - Unable or unlikely to complete study procedures (e.g., planned major surgery, anticipated move, travel barrier) - Communication or cognitive impairment that limits participation in treatment or study procedures. |
Country | Name | City | State |
---|---|---|---|
United States | University of Utah | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
University of Utah |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Pain Catastrophizing | Change in pain catastrophizing from baseline through 6-week follow-up will be assessed with the Pain Catastrophizing Scale (4 question version). Scores range from 0 to 20, with higher scores reflecting greater pain catastrophizing. | Will be completed at baseline, week 2, and week 6. | |
Other | Well-Being | Change in well-being from baseline through 6-week follow-up will be assessed with the World Health Organization Well-Being Scale (5 question version). Scores range from 0 to 25, with higher scores indicating greater well-being. | Will be completed at baseline, week 2, and week 6. | |
Other | Depression | Change in depression from baseline through 6-week follow-up will be assessed with the Patient Health Questionnaire-2. Scores range from 0 to 6, with higher scores reflecting greater depression. | Will be completed at baseline, week 2, and week 6. | |
Other | Anxiety | Change in anxiety from baseline through 6-week follow-up will be assessed with the Generalized Anxiety Disorder 2-item. Scores range from 0 to 6, with higher scores reflecting greater anxiety. | Will be completed at baseline, week 2, and week 6. | |
Other | Mindful Reappraisal of Pain Sensations | Change in Mindful Reappraisal of Pain Sensations from baseline through 6-week follow-up will be assessed with the Mindful Reappraisal of Pain Sensations Scale. Scores range from 0 to 54, with higher scores indicating greater mindful reappraisal of pain sensations. | Will be completed at baseline, week 2, and week 6. | |
Other | Trait Self-Transcendence | Change in trait self-transcendence from baseline through 6-week follow-up will be assessed with the Nondual Awareness Dimensional Assessment - Trait Version. Scores range from 0 to 52, with higher scores reflecting greater trait self-transcendence. | Will be completed at baseline, week 2, and week 6. | |
Other | Decentering | Change in decentering will be measured with the state version of the Metacognitive Processes of Decentering scale. Scores range from 0 to 10, with higher scores reflecting greater decentering. | Will be completed immediately before and after each of the two, 1-hour sessions of the One MORE intervention. | |
Other | State Self-Transcendence | Change in self-transcendent state will be measured with the Nondual Awareness Dimensional Assessment - State Version. Scores range from 0 to 10, with higher scores reflecting greater self-transcendence. | Will be completed immediately before and after each of the two, 1-hour sessions of the One MORE intervention. | |
Other | State Anxiety | Change in state anxiety will be measured with an individual item ("How anxious are you, right now?") rated on a numeric rating scale. Scores range from 0 to 10, with higher scores reflecting greater acute anxiety. | Will be completed immediately before and after each of the two, 1-hour sessions of the One MORE intervention. | |
Primary | Pain Intensity & Interference | Change in pain intensity and interference from baseline through 6-week follow-up will be assessed with the Pain, Enjoyment, and General Activity scale. Scores range from 0 to 30, with higher scores reflecting greater pain intensity/interference. | Will be completed at baseline, week 2, and week 6. | |
Secondary | Acute Pain | Change in acute pain will be measured with two individual items ("How much pain are you in, right now?", and "How unpleasant is your pain, right now?") rated on a numeric rating scale. Scores range from 0 to 10, with higher scores reflecting greater acute pain. | Will be completed immediately before and after each of the two, 1-hour sessions of the One MORE intervention. | |
Secondary | Acceptability | Acceptability will be measured with two individual items ("How acceptable did you find the strategies for managing your pain?") and ("How likely would you be to recommend this therapy to someone else dealing with chronic pain?") Scores range from 0 to 10, with higher scores indicating greater program acceptability. | Will be completed immediately after the second of the two, 1-hour sessions of the One MORE intervention. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|